<DOC>
	<DOCNO>NCT01651728</DOCNO>
	<brief_summary>The objective ass effect simvastatin immunology , inflammatory , coagulation response , mortality elderly pneumonia base . The primary outcome mortality event . The hypothesis study simvastatin therapy reduce mortality elderly pneumonia .</brief_summary>
	<brief_title>Effect Simvastatin Pneumonia Prognosis Elderly Patients</brief_title>
	<detailed_description>Elderly patient diagnose pneumonia get information signing inform consent include trial . Simvastatin 20 mg administer intervention group , control group receive placebo . Both group receive drug ( placebo ) 30 day . Baseline data collect within 24 hour admission . Then subject follow 30 day . At 7th day , patient underwent several laboratory test , i.e . serum TNF-α ( Tumor Necrosis Factor alpha ) , IFN-ϒ Interferon gamma ) , CRP ( C-Reactive Protein ) , PAI-1 ( Plasminogen Activator Inhibitor-1 ) . Death cause 30 day record .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Elderly patient pneumonia Severe septic condition Hepatic Cirrhosis Acute coronary disease Total cholesterol high low In anticoagulant therapy In steroid therapy immunosuppressant therapy Have refuse join study</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Simvastatin</keyword>
	<keyword>Pneumonia</keyword>
	<keyword>Elderly</keyword>
	<keyword>TNF-α</keyword>
	<keyword>IFN-ϒ</keyword>
	<keyword>PAI-1</keyword>
	<keyword>CRP</keyword>
</DOC>